Tobacco and Public Health - TCSC Indonesia

to tobacco product ingredients and emissions, so to should the reinforcing effects of
tobacco products be influenced by the ingredients and emissions of tobacco products.
Just as it should be possible to reduce cigarette toxicity even short of eliminating
toxicity, it may be possible to reduce tobacco addictiveness even without eliminating
the nicotine or eliminating addiction potential (Henningfield and Zeller 2003; World
Health Organization 2003). Behavioral pharmacological analyses may then prove to be
as important as toxicology studies in guiding the regulation of tobacco product ingredients
and emissions.
Acknowledgments
Preparation of this paper was supported, in part, by a Robert Wood Johnson
Foundation Emerging Leadership Program Award to B.E. Garrett, and a Robert Wood
Johnson Foundation Innovators Combating Substance Abuse Award to
J.E. Henningfield. J.E. Henningfield provides consulting services regarding treatments
for tobacco dependence to GlaxoSmithKline Consumer Health Care through Pinney
Associates. J.E. Henningfield also has a financial interest in a nicotine replacement
product under development, and serves as an expert witness in litigation against the
tobacco industry by the U.S. Department of Justice and other plaintiffs. We greatly
appreciate the editorial assistance of Christine A. Rose, whose efforts were supported
by the Innovators award to JEH.
References
BRIDGETTE E. GARRETT ET AL. 161
American Psychiatric Association (APA) (1994). Diagnostic and Statistical Manual of Mental
Disorders, 4th ed. Washington (DC): American Psychiatric Association.
Balfour, D. J. K. and Benwell, M. E. M. (1993). The role of brain dopamine systems in the
psychopharmacological responses to nicotine. Asia Pac J Pharmacol, 8, 153–67.
Bardo, M. T., Bevins, R. A., Klebaur, J. E., Crooks, P. A., and Dwoskin, L. P. (1997). Nornicotine
partially substitutes for (+)-amphetamine in a drug discrimination paradigm in rats. Pharmacol
Biochem Behav, 58, 1083–7.
Bardo, M. T., Green, T. A., Crooks, P. A., and Dwoskin, L. P. (1999). Nornicotine is self-administered
intravenously by rats. Psychopharmacol, 146, 290–6.
Bardo, M. T. and Bevins, R. A. (2000). Conditioned place preference: what does it add to our preclinical
understanding of drug reward? Psychopharmacol, 153, 31–43.
Benowitz, N. L. (1996). Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol
Toxicol, 36, 597–613.
Benwell, M. E. and Balfour, D. J. K. (1992). The effects of acute and repeated nicotine treatment on
nucleus accumbens dopamine and locomotor activity. Br J Pharmacol, 105, 849–56.
Brioni, J. D., Kim, D. J., and O’Neill, A. B. (1996). Nicotine cue: lack of effect of the α7 nicotinic
receptor antagonist methyllycaconitine.Eur J Pharmacol, 301, 1–5.
Champtiaux, N., Han, Z. Y., Bessis, A., Rossi, F. M., Zoli, M., Marubio, L., et al. (2002). Distribution
and pharmacology of α6-containing nicotinic acetylcholine receptors analyzed with mutant mice.
J Neurosci, 22, 1208–17.